| Author |
Cells lines |
Design |
Result |
Transport |
Ref |
| Walther W. et al. |
MCF-7
HCT116
SKMel-5
Panc-1 |
In Vitro
In Vivo |
Effective against
MCF-7
HCT116
(overexpressing claudin-3-, -4-) |
wtCPE
optCPE |
[81] |
| MichaelsenS. R.et al. |
GLC-14, GLC-16,
GLC-19, NCI-H69,
H69-VP, H69-CPR,
H69-DAU, H69-BCNU |
In Vitro
In Vivo |
Effective both in chemosensitive andchemoresistant celllines |
INSM1 promoter-driven SG |
[47] |
| Mader R.M. et al. |
CCL227 (with low and Intermediate phenotypes) |
In Vitro |
Effective with 100%Activation |
Adenoviral cosmids |
[8] |
| Bondanza A. et al. |
Leukemia (mouse) |
In VitroIn Vivo |
Effective withIL-7 receptorexpression(HA-1-, H-Y-) |
Herpes simplex virusThymidine kinase (tk) |
[45] |
| Xu Y. et al. |
Lewis Lung Cancer
A549 |
In VitroIn Vivo |
Combination IL-12 and suicide genetherapy enhances the antitumor effectas a factor modifying the tumor microenvironment |
AdCMV(-), AdhTERTHRP, AdCMVmIL-12 |
[46] |
| Sia KC. et al. |
HCC 26-1004 |
In VitroIn Vivo |
Effective HSV-1 amplicon viral vector and 5-FU administration |
HSV-1 amplicon viral Vector coupled with yCD |
[9] |
| Li S. et al. |
C17.2 NSC line |
In VitroIn Vivo |
ATRA enhanced the HSV-tk/GCV |
HSVtk/GCV |
[30] |
| FinocchiaroM.E.L. et al. |
sarcoma |
In Vivo |
Effective MicroenvironmentControl and Distant metastasis |
Lipid-complexed plasmid Bearing IFN-β and suicide genes co-administered with ganciclovir (ISG) |
[42] |
| Leng A. et. al. |
Human colon carcinoma(Lovo) cell line |
In VitroIn Vivo |
Anti-VEGF-A-Suicide gene therapy |
5-FC, CPNP-shVEGF-CDTK |
[43] |
| Liu T. et. al. |
SGC7901 human gastricCancer cell line |
In vitroIn Vivo |
Anti-VEGF-Suicide gene therapy |
5-FC, triple gene vector ExpressingVEGF-shRNA and fusion suicide geneyCDglyTK delivered by CPNPs |
[44] |
| Finzi et. al. |
Human HT29 and murineDHDK12 pro-b |
In VitroIn Vivo |
MTX, aphidicolinandara-C. The rate of apoptosis increased two-fold in MTX-treated DHDK12 cells after treatment with GCV. |
HSVtk-GCV |
[25] |
| Niu H. et. al. |
VX2 liver cancer |
In Vivo |
Effective with lipiodolembolism and WTp53 |
TK/CD plus intraperitonealInjection of GCV at 100mg/(kg.d)and 5-FC at 500mg/(kg.d) |
[26] |
| MarukawaY. et. al. |
HCC |
In vitroIn Vivo |
Effective Mac-1, CD4,CD8a-positive and TNF increase |
-HSV-tk/GCV and MCP-1-rAd harboring human MCP-1and the membrane-spanning domain of the tumor cell surface |
[27] |
| Kosaka H. t. al. |
9L rat glioma cells and 293 cells |
In vitroIn Vivo |
MSC-EGFP or MSC-CD-5-FCresulted in significant prolongation of survival |
AdexCAEGFPAdexCACD |
[39] |
| Schmidt M.et. al. |
Head and Neck squamous carcinoma cell line FADU |
In Vitro |
Effective with deletion Mutant of ETA as a Targetgene |
Gene Switch System |
[41] |
| Cottin S. et. al. |
Glioblastoma |
In Vitro |
Effective against Cx43 cytoplasmic localization |
Lentiviral delivery of HSV-tk/GCV |
[40] |
| Kakinoki K. et. al. |
HCC |
In vitroIn Vivo |
Effective against metastasis and controlof microenvironment |
CCL2/MCP-1HSV-tk/GCV |
[49] |
| Sun X. et. al. |
R3327-AT rat prostateCarcinoma cells |
In VitroIn Vivo |
Effective against hypoxic cells |
Bifunctionalcytosine deaminase (CD) anduracil phosphoribosyltransferase(UPRT) with 5-FC and radiotherapy |
[48] |
| Amano S. et. al. |
C6 glioma cells |
In VitroIn Vivo |
Safety evaluation of theStem cell therapy in braintissue |
Rat MSCtk/GCV |
[65] |
| Zhao Y. et. al. |
U87 glioma and H4 cells |
In VitroIn Vivo |
Effective as cellular Vehicle for targeted suicide genetherapy |
Tumor-tropic neural stem cells, HSV-tk/GCV |
[38] |
| Wang C. et. al. |
NCI-H460-GFP cells |
In VitroIn Vivo |
Effective brain metastasistreatment |
NSC line expressingCD and TK |
[37] |
| Yin X. et. al. |
Bladder cancer withN-methyl-nitrosoureaperfusion |
In VitroIn Vivo |
Effective both in extrisincand intrisincpapoptosispathways |
BI-HSV-tk/GCV |
[36] |
| Leveille S. et. al. |
Prostate PC3, Breast MCF7,TSA mammary Adenocarcinoma, B-Lymphoma Karpas-422,Melanoma B16-F10 |
In VitroIn Vivo |
Synergistic effect of (VSV)-ΜΔ51 and 5FC |
Combination (VSV)-ΜΔ51-Expressing(CD::UPRT)-5FC |
[85] |
| Cramer F. et. al. |
SCLC: GLC16, DMS53 andNCI-H69 and NSCLCcancer lines: H1299 and A549 |
In Vitro |
Improved plasmidnucleardelivery |
NFnB-DTS in anYCD-YUPRT (SCD) |
[28] |
| Li J. et. al. |
SGC7901 human gastric cancer cell line |
In Vitro |
Effective Cell apoptosis |
YCDglyTK and Htert with CPNPs /Novel vector pcDNA3.1(-)hTERT-ShRNA / YCDglyTK |
77 |
| Duan X. et. al. |
C-26 |
In VitroIn Vivo |
DMP Delivered Survivin-T34A gene DMP/S-T34A) which induced apoptosis |
DOTAP and MPEG-PCL hybrid micelles (DMP) |
[50] |
| Tang Q et. al. |
Human hepatic cell line (HepG2) |
In VitroIn Vivo |
Survival time and apoptosis |
Intratumorally injected KDR-TK, AFP-TK and microbubbleContrast agent with 5-FC and GCV |
[51] |
| ZarogoulidisP. et. al. |
Lewis lung cancer,SCLC, NSCLC patients |
Animals
Humans |
Survival and malignant pleural effusion control with higherefficiency observed for SCLC. |
Ad.CD+5-FC |
[6] |
| Yi B. et. al. |
Review |
Review |
Review |
Review |
[35] |
| Qiu Y. et. al. |
A549, 16HBE, SPC-A-1 AndNCI-H520 |
In Vitro |
Specific CA-positive Target gene expression |
CEA promoter and double suicide genes TK and CD.pCEA-TK/CD |
[29] |
| Won Y. et. al. |
C6, U87, F98 and 9L |
In VitroIn Vivo |
Tumor growth Suppressionand locomotor functionmaintenance |
rPOA/HSV-tk/GCV |
[32] |
| Akerstrom V. et. al. |
Neuroendocrine tumors:NCI-H69, NCI-H1155, NCI-H727, DMS53, U87MG,IMR-32, S-N-SH, SK-N-BE(2),Y79, WERI-Rb1, HeLa, ANC-1,BEAS, RIN, D283 Med, HepG2 |
In VitroIn Vivo |
Enhanced antitumor activity over the RSV control |
INSM1 promoter, HSV-tk to generate Ad-K5 virus |
[31] |
| Lu M. et. al. |
Prostate |
Human |
Initiatedand recruiting at the time of publication |
Replication-Competent Adenovirus- mediated suicide gene therapy |
[33] |
| Ma S. et. al. |
MCF-7 and MDA-MB-231Breast cell lines |
In VitroIn Vivo |
Effective antitumor control |
Drosophila melanogaster(Dm-dNK) |
[34] |
| Preuss E. et. al. |
G62 human glioblastoma cellLine, A549 human lung Carcinoma, SW620 human Colorectal adenocarcinomaCell line and IPC298 HumanMelanoma cell line |
In VitroIn Vivo |
Continuous complete remission |
TK.007 novel suicide gene |
[95] |
| Ahn Y. et. al. |
CT26 murine colon adenocarcinoma cells andAGS human gastric adenocarcinoma cells |
In VitroIn Vivo |
Effective combination Suicide immune therapy |
shRNA-lentivirusand Ad5.CMV.HSV.tk |
[24] |
| Gruber C. et. al. |
SCC |
In VitroIn Vivo |
Efficient transfection of RDEB SCC |
SLO=PTM |
[96] |
| Xiong J. et. al. |
HeLa human cervical cancer Cells, A549 human lung Adenocarcinoma cells,MHCC97 human hepatomaCarcinoma cells and hELNormal human embryonivLung cells |
In Vitro |
Combinational cancer Promoter responsive to irradiation |
Chimeric hTERT promoters, CArG |
[82] |
| Luo X. et. al. |
SGC7901 human gastricCancer cell lines |
In VitroIn Vivo |
Higher efficiency withdouble suicide gene therapy CD/TK |
Double suicide gene therapyAd-survivin/GFP andAd-survivin/CD/TK |
[59] |
| Freytag S. O. et. al. |
Prostate cancer |
Human |
Transgene expression up to 3 weeks, PSA decline, Acute urinary and gastrointestinal toxicities |
Cytosine deaminasa(CD)/herpes simplexvirus thymidine kinase (HSV-1 TK) and 3D-CRT |
[92] |
| Pandha H. S. et. al. |
Breast cancer |
Human |
Efficient selectivity against erb-2 |
Therapeutic cassette that contains the Escherichia colicytosinedeaminase gene drivan by the tumor-specific erb-2 promoter |
[57] |
| Li N. et. al. |
HCC cancer |
Human |
Recurrence free survival |
Adjuvant ADV-TK |
[91] |
| Voges J. et. al. |
Glioblastoma |
Human |
Inhomogeneity of tissue formulation distribution |
HSV-1-tk liposomal vector |
[88] |
| Nasu Y. et. al. |
Prostate |
Human |
No serum cytokine changes after treatment,decreased PSA values,Increased CD8+/HLA-DR+This study confirmed thesafety profile at the surrogate markerof HSV-tk gene therapy. |
Ad.HSV-tk/GCV |
[89] |
| Rainov N.G. et. al. |
Glioblastoma |
Human |
Surgical resection and Radiotherapy or standardtherapy plus adjuvant gene therapy during surgery. Progression-free median survival in the gene group was 180 days compared with 183 days of control group |
RV-HSV-tk/GCV |
[76] |
| Xu F. et. al. |
Head and Neck |
Human |
Local response |
Intratumoral RV-HSV-tk/GCV |
[90] |
| Nemunaitis J.et. al. |
Refractory cancer patients |
Human |
Salmonella bacterium can be utilized as a delivery vehicle of thecytosine deaminase gene to malignant tissue with low dose 3 x 107 CFU/m2 efficiently. |
TAPET-CD |
[94] |
| Freytag S. O.et. al. |
Pancreas |
Human |
Augments radiotherapytreatment of pancreaticcancer without excessivetoxicity |
Ad5-yCD/mutTKSR39rep-ADPHSV-1 TK SR39 |
[93] |
